Palmitoyl Dipeptide-6

What is Palmitoyl Dipeptide-6?

Palmitoyl Dipeptide-6 is a lipidated cosmetic dipeptide — a two-amino-acid sequence (most commonly reported in the published literature as valine-tryptophan, abbreviated Pal-VW) conjugated to palmitic acid to improve penetration through the lipid-rich stratum corneum. It belongs to the broader palmitoyl peptide family that also includes Matrixyl (Palmitoyl Pentapeptide-4), Palmitoyl Tripeptide-1, and Palmitoyl Tetrapeptide-7, all of which share the same delivery strategy: a short peptide signal attached to a C16 fatty acid that partitions into the outer skin barrier and carries the peptide toward viable epidermis. It is typically included in finished cosmetic products as part of anti-aging serums and creams, and is often marketed as a 'retinol-like' or 'retinol alternative' topical active. That framing is marketing shorthand — Palmitoyl Dipeptide-6 does not bind retinoic acid receptors the way retinoids do. Its proposed mechanism is at the level of fibroblast signaling and extracellular-matrix remodeling, which is a different biological pathway reaching similar appearance-related endpoints. Published clinical human efficacy data specifically for Palmitoyl Dipeptide-6 in isolation is limited; most evidence is mechanistic, in vitro, or from supplier-associated formulation studies.

What Palmitoyl Dipeptide-6 Is Investigated For

Palmitoyl Dipeptide-6 is a cosmetic topical peptide positioned as a 'retinol-like' anti-aging ingredient for fine-line reduction, skin smoothing, and firmness. It is best understood in context: it sits in the same structural family as Matrixyl and Palmitoyl Tripeptide-1 — a short peptide conjugated to palmitic acid for stratum-corneum penetration — and shares the general cosmetic-peptide positioning of fibroblast and extracellular-matrix signaling rather than any retinoid-like receptor activity. The 'retinol alternative' framing is marketing shorthand and is not supported by head-to-head clinical trials showing equivalence with topical retinoids, which have decades of dermatologic evidence for photoaging. Published human RCT data specifically for isolated Palmitoyl Dipeptide-6 at clinically relevant concentrations and durations is thin; most evidence is mechanistic, in vitro, or from supplier-associated formulation studies where the ingredient is combined with other actives. Honest positioning: a plausible cosmetic active in the palmitoyl peptide family, likely gentler than retinoids and compatible with layered anti-aging routines, with a limited independent clinical evidence base and effect sizes that should be expected to be modest.

How It Works

Palmitoyl Dipeptide-6 is a short two-amino-acid skincare peptide attached to a fatty acid (palmitic acid) that helps it slip through the outer skin barrier. Once inside, it is proposed to signal skin cells — specifically fibroblasts — to support the structural proteins (like collagen) that keep skin firm and smooth. It is often marketed as a 'retinol alternative,' but it does not act on the same receptors as retinoids. It is a different pathway toward similar appearance-related goals, and the clinical evidence for its specific effects is thin.

Palmitoyl Dipeptide-6 is a lipopeptide built from a two-amino-acid core (most commonly reported in the published cosmetic literature as valine-tryptophan, Val-Trp or Pal-VW) covalently linked at the N-terminus to palmitic acid, a C16 saturated fatty acid. The palmitoyl modification is the dominant design feature shared across the palmitoyl peptide family (Matrixyl, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Palmitoyl Dipeptide-5 and -6): a bare short peptide is hydrophilic and partitions poorly into the lipid-rich stratum corneum, whereas the same peptide lipidated with palmitate becomes amphipathic and penetrates the outer skin barrier more readily — though only a modest fraction of applied peptide ultimately reaches viable epidermis in typical cosmetic vehicles. The proposed biological action is at the level of fibroblast and extracellular-matrix signaling rather than retinoic-acid-receptor activation. Published work on short cosmetic peptides in this class has described effects on extracellular-matrix protein expression (collagens, fibronectin, glycosaminoglycans) and on fibroblast contractility or morphology in cell culture, consistent with a matrikine-style signaling rationale. The specific receptor or primary target protein mediating Palmitoyl Dipeptide-6's activity is not well characterized in the independent peer-reviewed literature; much of the supporting rationale is extrapolated from the broader palmitoyl peptide and cosmetic-matrikine category rather than from dedicated studies of the dipeptide in isolation. The 'retinol-like' marketing framing refers to a similar appearance-level endpoint (fine-line reduction, smoother skin over time), not to shared pharmacology — retinoids operate through nuclear retinoic acid receptors with global epidermal effects, and Palmitoyl Dipeptide-6 does not engage that pathway.

Evidence Snapshot

Forms & Administration

Topical application in serums, creams, and anti-aging formulations, typically as one ingredient among several cosmetic actives rather than as a stand-alone product. Frequently combined with other palmitoyl peptides (Matrixyl, Palmitoyl Tripeptide-1), copper peptides (GHK-Cu), neuropeptides (Argireline, SNAP-8), and established actives (retinoids, niacinamide, hyaluronic acid, vitamin C — usually applied at a different time of day to avoid pH-mediated destabilization). Skin penetration is the rate-limiting step for cosmetic peptides in general; vehicle and formulation affect real-world delivered dose more than nominal label concentration above a certain threshold. Not for injection — cosmetic peptide preparations are not sterile, are not formulated for parenteral use, and have no clinical rationale for injection.

Common Questions

Safety Profile